NIH has granted $4 million to the company UC Davis founded to pursue this SEH inhibitor approach to treating neuropathic pain.

http://www.centralvalleybusinesstime.../001/?ID=29766

"Now known as EC5026, the compound is “a potent, orally active and a non-narcotic analgesic that does not adversely affect the brain, gastrointestinal tract, or cardiovascular system,” says Alan Buckpitt, the company's vice president of pharmacology and emeritus professor of molecular biosciences at the UC Davis School of Veterinary Medicine. “The compound effectively treats pain in preclinical models at low oral doses with no apparent adverse or addictive effects. Preclinical studies demonstrate efficacy that exceeds current therapies for diabetic neuropathy.”"

________